FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2917270564> ?p ?o ?g. }

• W2917270564 endingPage "1292" @default.
• W2917270564 startingPage "1284" @default.
• W2917270564 abstract "Prostate-specific membrane antigen (PSMA)-targeted radioligands have played an important role in the diagnosis of prostate cancer. In this study, we developed an Al18F-labeled radiotracer and evaluated its potential for prostate cancer imaging. Methods: Al18F-PSMA-BCH (BCH is Beijing Cancer Hospital) was efficiently prepared manually. The binding affinity to PSMA was evaluated in vitro using the 22Rv1 (PSMA-positive) cell line. Small-animal PET imaging, biodistribution studies of Al18F-PSMA-BCH in mice bearing 22Rv1 and PC-3 (PSMA-negative) xenografted tumors, and a comparison with 68Ga-PSMA-617 in mice bearing LNCaP tumors were performed. PET/CT imaging was performed on 11 newly diagnosed prostate cancer patients at 1 and 2 h after injection. Biodistribution and preliminary efficacy were evaluated, and radiation dosimetry was estimated using OLINDA/EXM 2.0 software. Results: Al18F-PSMA-BCH was prepared within 30 min and was found to bind to PSMA with a dissociation constant of 2.90 ± 0.83 nM. Small-animal PET imaging of Al18F-PSMA-BCH could clearly differentiate 22Rv1 tumors from PC-3 tumors, as confirmed by ex vivo biodistribution data (7.87% ± 2.37% and 0.54% ± 0.22% injected dose/g at 1 h in 22Rv1 and PC-3 tumors, respectively). The uptake of Al18F-PSMA-BCH in 22Rv1 tumors could be substantially blocked by excess ZJ-43, a PSMA inhibitor. High-level accumulation of Al18F-PSMA-BCH was observed in PSMA-expressing organs, with increased uptake at later time points. Thirty-seven tumor lesions were detected in 11 patients, and the SUVmax in 27 lesions increased between 1 and 2 h after injection (10.60 vs. 14.11). The SUVmax in primary lesions in patients with high-risk prostate cancer was higher than that in patients with intermediate-risk prostate cancer. The kidneys received the highest estimated dose, 0.135 mGy/MBq, and the effective dose was 0.016 mGy/MBq. Conclusion: Al18F-PSMA-BCH was conveniently prepared with a reasonable yield within 30 min and showed a promising imaging capability for prostate cancer with reasonable radiation exposure. Al18F-PSMA-BCH can be used for prostate cancer imaging as a novel 18F PET radiotracer." @default.
• W2917270564 created "2019-03-02" @default.
• W2917270564 creator A5003360183 @default.
• W2917270564 creator A5009072674 @default.
• W2917270564 creator A5015105154 @default.
• W2917270564 creator A5039352081 @default.
• W2917270564 creator A5048279362 @default.
• W2917270564 creator A5048800314 @default.
• W2917270564 creator A5052913425 @default.
• W2917270564 creator A5053846840 @default.
• W2917270564 creator A5067981325 @default.
• W2917270564 creator A5070745094 @default.
• W2917270564 creator A5072295544 @default.
• W2917270564 date "2019-02-22" @default.
• W2917270564 modified "2023-10-16" @default.
• W2917270564 title "Preclinical Evaluation and Pilot Clinical Study of Al¹⁸F-PSMA-BCH for Prostate Cancer PET Imaging" @default.
• W2917270564 cites W1508058484 @default.
• W2917270564 cites W1517749817 @default.
• W2917270564 cites W1937872520 @default.
• W2917270564 cites W1998345392 @default.
• W2917270564 cites W2030940240 @default.
• W2917270564 cites W2045610508 @default.
• W2917270564 cites W2054075039 @default.
• W2917270564 cites W2120873855 @default.
• W2917270564 cites W2125363072 @default.
• W2917270564 cites W2134019417 @default.
• W2917270564 cites W2161309377 @default.
• W2917270564 cites W2303295229 @default.
• W2917270564 cites W2402590797 @default.
• W2917270564 cites W2461073194 @default.
• W2917270564 cites W2469717780 @default.
• W2917270564 cites W2471060742 @default.
• W2917270564 cites W2508622292 @default.
• W2917270564 cites W2524354109 @default.
• W2917270564 cites W2525349940 @default.
• W2917270564 cites W2526522995 @default.
• W2917270564 cites W2534848937 @default.
• W2917270564 cites W2541665535 @default.
• W2917270564 cites W2547821596 @default.
• W2917270564 cites W2551224209 @default.
• W2917270564 cites W2553708763 @default.
• W2917270564 cites W2554535346 @default.
• W2917270564 cites W2556290530 @default.
• W2917270564 cites W2558756811 @default.
• W2917270564 cites W2561138750 @default.
• W2917270564 cites W2565349509 @default.
• W2917270564 cites W2570618306 @default.
• W2917270564 cites W2570738088 @default.
• W2917270564 cites W2574390829 @default.
• W2917270564 cites W2580660759 @default.
• W2917270564 cites W2605186041 @default.
• W2917270564 cites W2607793510 @default.
• W2917270564 cites W2619427920 @default.
• W2917270564 cites W2731354724 @default.
• W2917270564 cites W2753504798 @default.
• W2917270564 cites W2765143946 @default.
• W2917270564 cites W2788948557 @default.
• W2917270564 cites W2800232471 @default.
• W2917270564 doi "https://doi.org/10.2967/jnumed.118.221671" @default.
• W2917270564 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30796170" @default.
• W2917270564 hasPublicationYear "2019" @default.
• W2917270564 type Work @default.
• W2917270564 sameAs 2917270564 @default.
• W2917270564 citedByCount "49" @default.
• W2917270564 countsByYear W29172705642019 @default.
• W2917270564 countsByYear W29172705642020 @default.
• W2917270564 countsByYear W29172705642021 @default.
• W2917270564 countsByYear W29172705642022 @default.
• W2917270564 countsByYear W29172705642023 @default.
• W2917270564 crossrefType "journal-article" @default.
• W2917270564 hasAuthorship W2917270564A5003360183 @default.
• W2917270564 hasAuthorship W2917270564A5009072674 @default.
• W2917270564 hasAuthorship W2917270564A5015105154 @default.
• W2917270564 hasAuthorship W2917270564A5039352081 @default.
• W2917270564 hasAuthorship W2917270564A5048279362 @default.
• W2917270564 hasAuthorship W2917270564A5048800314 @default.
• W2917270564 hasAuthorship W2917270564A5052913425 @default.
• W2917270564 hasAuthorship W2917270564A5053846840 @default.
• W2917270564 hasAuthorship W2917270564A5067981325 @default.
• W2917270564 hasAuthorship W2917270564A5070745094 @default.
• W2917270564 hasAuthorship W2917270564A5072295544 @default.
• W2917270564 hasBestOaLocation W29172705641 @default.
• W2917270564 hasConcept C121608353 @default.
• W2917270564 hasConcept C126322002 @default.
• W2917270564 hasConcept C185592680 @default.
• W2917270564 hasConcept C202751555 @default.
• W2917270564 hasConcept C20417620 @default.
• W2917270564 hasConcept C2775842073 @default.
• W2917270564 hasConcept C2777807558 @default.
• W2917270564 hasConcept C2779723316 @default.
• W2917270564 hasConcept C2780192828 @default.
• W2917270564 hasConcept C2989005 @default.
• W2917270564 hasConcept C502942594 @default.
• W2917270564 hasConcept C55493867 @default.
• W2917270564 hasConcept C71924100 @default.
• W2917270564 hasConceptScore W2917270564C121608353 @default.
• W2917270564 hasConceptScore W2917270564C126322002 @default.
• W2917270564 hasConceptScore W2917270564C185592680 @default.

• next